Conduit Pharmaceuticals (CDT) Stock Statistics & Valuation Metrics

Conduit Pharmaceuticals has a market cap or net worth of $5.44M. The enterprise value is ―.

Conduit Pharmaceuticals has 2,925,862 shares outstanding. The number of shares has decreased by -2.65% in one year.

Conduit Pharmaceuticals’s return on equity (ROE) is 2.62 and return on invested capital (ROIC) is -1922.57%.

The current PE Ratio of Conduit Pharmaceuticals is ―. Conduit Pharmaceuticals’s PEG ratio is ―.

In the last 12 months, Conduit Pharmaceuticals had revenue of 922.22M and earned -17.80M in profits. Earnings per share was -20.53.

In the last 12 months, operating cash flow was 83.66M and capital expenditures -57.39M, giving a free cash flow of 26.26M billion.

Conduit Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Conduit Pharmaceuticals upcoming earnings date is ―, ―.

Conduit Pharmaceuticals as a current ratio of 0.25, with Debt / Equity ratio of 110.83%

In the past 12 months, Conduit Pharmaceuticals has paid 0.00 in taxes.

Conduit Pharmaceuticals EV to EBITDA ratio is -13.65, with an EV/FCF ratio of -22.22.

Conduit Pharmaceuticals has $301.49M in cash and marketable securities with ― in debt, giving a net cash position of $1.07B billion.

Gross margin is 56.69%, with operating margin of -1.67%, and net profit margin of -1.93%.

The average price target for Conduit Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―